OXB - Ticker AI Digest

Oxford BioMedica PLC 📰 1
Desk Snapshot GO VIP Login
Important AI Risk Notice

Charts, catalyst summaries, AI scores, forecasts and price context are AI-driven and can hallucinate, lag or miss market-changing information.

Not investment advice. Markets can move fast and any trade or allocation decision remains your responsibility.
AI can hallucinate. Summaries, rankings, forecasts and commentary can be wrong, incomplete or misleading.
AI-driven data only. Signals, dates, prices, sentiment and automation outputs may be delayed, estimated or stale.
Always verify externally. Confirm prices, filings, broker notes and trade setup details with independent sources before acting.
Mobile Command Deck
Oxford BioMedica PLC in one cleaner mobile flow.
Tap straight into the module you want. No sideways tab hunt, just a clean route into charts, news, Today’s AI, and the deeper desks.
OXB Data 2026-03-26 Preview Mode
Core Deck
Deep Dive Modules

Digested News

Today's Catalysts (OXB) 1
OXB 06:01
Oxford BioMedica PLC
Preliminary results for the year ended 31 Dec 2025
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Oxford Biomedica PLC (OXB) reported strong preliminary results for the year ended 31 December 2025, highlighting strategic execution, robust revenue growth, and positive Operating EBITDA. Key financial highlights include
**Revenue Growth** 33% increase to £170.9 million (constant currency), driven by growth in lentiviral vector GMP manufacturing, increased client progression, and expansion in procurement and storage services.
**Operating EBITDA** Achieved a profit of £8.1 million (constant currency), up from a £15.3 million loss in 2024, reflecting revenue growth and cost management.
**Revenue Backlog** Increased by 36% to £204 million, indicating strong future revenue potential.
**Strategic Expansion** Acquired an FDA-approved commercial-scale viral vector manufacturing facility in Durham, NC, enhancing global CDMO capabilities.
**New Commercial Agreement** Signed a multi-year agreement with Bristol Myers Squibb (BMS) for lentiviral vector manufacturing post-period.
**Financial Guidance** Projected 2026 revenues of £220-240 million with a 10% Operating EBITDA margin, and medium-term revenue growth of 25-30% with margins rising to at least 20% by 2027.
Operationally, OXB expanded its global CDMO network, improved efficiency, and strengthened its balance sheet through equity raises and loan facilities. The company also advanced its innovation efforts, particularly in AAV and lentiviral vector technologies, and enhanced its ESG commitments. The acquisition of the Durham facility and strategic partnerships underscore OXBs position as a global leader in cell and gene therapy CDMO services, poised for sustained growth and profitability.
Financial Metric20242025Year-on-Year Change
Revenue£128.8 million£170.9 million (CC)33% increase
Operating EBITDA£(15.3) million£8.1 million (CC)Profitability achieved
Underlying Operating EBITDA (excluding Durham gain)N/A£3.3 million (CC)New metric introduced
Revenue BacklogN/A£204 million36% increase
Contracted Value of Orders£186 million£224 million20% increase
Net Cash£20.6 million£55.4 million169% increase
Debt (Loans)£39.79 million£41.488 million4.3% increase
### Key Observations: 1. **Revenue Growth**: Revenue increased by 33% year-on-year, driven by growth in lentiviral vector GMP manufacturing, increased client progression through clinical development, and growth in procurement and storage services. 2. **EBITDA Improvement**: Operating EBITDA turned positive, achieving £8.1 million (CC) compared to a loss of £15.3 million in 2024, reflecting strong revenue growth and cost control. 3. **Debt Increase**: Debt increased slightly by 4.3%, primarily due to new loans drawn down and interest accruals. 4. **Cash Position**: Net cash position significantly improved, increasing by 169% to £55.4 million, supported by equity raises and improved operating performance. 5. **Order Book Strength**: Revenue backlog and contracted value of orders both increased substantially, indicating strong future revenue visibility and continued growth.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 1
OXB 06:01
Oxford BioMedica PLC
Licensing agreement with VVMF
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
Oxford Biomedica (OXB) has entered into a licensing and option agreement with Viral Vector Manufacturing Facility (VVMF), an Australian CDMO, granting VVMF access to OXBs proprietary AAV and LV viral vector platforms. This five-year agreement, with a low single-digit million license fee and potential future payments, supports VVMFs development of viral vector manufacturing capabilities, particularly in the APAC region. The collaboration extends OXBs global reach, reinforces its position as a trusted viral vector CDMO, and positions Australia as a regional hub for high-quality cell and gene therapy manufacturing.
Agreement
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 1
OXB 06:01
Oxford BioMedica PLC
Preliminary results for the year ended 31 Dec 2025
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Oxford Biomedica PLC (OXB) reported strong preliminary results for the year ended 31 December 2025, highlighting strategic execution, robust revenue growth, and positive Operating EBITDA. Key financial highlights include
**Revenue Growth** 33% increase to £170.9 million (constant currency), driven by growth in lentiviral vector GMP manufacturing, increased client progression, and expansion in procurement and storage services.
**Operating EBITDA** Achieved a profit of £8.1 million (constant currency), up from a £15.3 million loss in 2024, reflecting revenue growth and cost management.
**Revenue Backlog** Increased by 36% to £204 million, indicating strong future revenue potential.
**Strategic Expansion** Acquired an FDA-approved commercial-scale viral vector manufacturing facility in Durham, NC, enhancing global CDMO capabilities.
**New Commercial Agreement** Signed a multi-year agreement with Bristol Myers Squibb (BMS) for lentiviral vector manufacturing post-period.
**Financial Guidance** Projected 2026 revenues of £220-240 million with a 10% Operating EBITDA margin, and medium-term revenue growth of 25-30% with margins rising to at least 20% by 2027.
Operationally, OXB expanded its global CDMO network, improved efficiency, and strengthened its balance sheet through equity raises and loan facilities. The company also advanced its innovation efforts, particularly in AAV and lentiviral vector technologies, and enhanced its ESG commitments. The acquisition of the Durham facility and strategic partnerships underscore OXBs position as a global leader in cell and gene therapy CDMO services, poised for sustained growth and profitability.
Financial Metric20242025Year-on-Year Change
Revenue£128.8 million£170.9 million (CC)33% increase
Operating EBITDA£(15.3) million£8.1 million (CC)Profitability achieved
Underlying Operating EBITDA (excluding Durham gain)N/A£3.3 million (CC)New metric introduced
Revenue BacklogN/A£204 million36% increase
Contracted Value of Orders£186 million£224 million20% increase
Net Cash£20.6 million£55.4 million169% increase
Debt (Loans)£39.79 million£41.488 million4.3% increase
### Key Observations: 1. **Revenue Growth**: Revenue increased by 33% year-on-year, driven by growth in lentiviral vector GMP manufacturing, increased client progression through clinical development, and growth in procurement and storage services. 2. **EBITDA Improvement**: Operating EBITDA turned positive, achieving £8.1 million (CC) compared to a loss of £15.3 million in 2024, reflecting strong revenue growth and cost control. 3. **Debt Increase**: Debt increased slightly by 4.3%, primarily due to new loans drawn down and interest accruals. 4. **Cash Position**: Net cash position significantly improved, increasing by 169% to £55.4 million, supported by equity raises and improved operating performance. 5. **Order Book Strength**: Revenue backlog and contracted value of orders both increased substantially, indicating strong future revenue visibility and continued growth.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 1
OXB 06:04
Oxford BioMedica PLC
Full year Trading Update and Notice of Results
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Oxford Biomedica PLC (OXB) released a full-year trading update for 2025, highlighting strong financial performance and strategic progress. Key points include
1. **Revenue Growth**FY 2025 revenues are expected to reach £166-169 million, a 30% increase from 2024 and nearly 90% growth since 2023, driven by sustained demand for viral vector services and operational efficiency.
2. **EBITDA Profitability**OXB achieved EBITDA profitability in 2025, with mid-to-high single-digit £ million Operating EBITDA, including a non-recurring gain from the Durham, NC acquisition. Underlying EBITDA (excluding the acquisition) is in line with guidance at low single-digit £ million.
3. **Contracted Orders**The contracted value of client orders increased by 20% to £224 million, reflecting strong demand from existing and new clients.
4. **Financial Position**OXB strengthened its balance sheet with a £60 million equity raise and a new $125 million loan facility, supporting capacity expansion and growth initiatives.
5. **Future Outlook**The company reiterated its guidance, expecting FY 2026 revenues of £220-240 million, with 25-30% annual growth in 2027 and 2028. EBITDA margins are projected to exceed 10% in 2026 and reach at least 20% in 2027, with long-term potential to approach 30%.
6. **Preliminary Results**OXB will announce its preliminary results for 2025 on March 26, 2026, with a virtual analyst briefing led by CEO Dr. Frank Mathias.
The update underscores OXBs successful execution of its CDMO strategy, strong commercial momentum, and optimism for continued growth and profitability in the coming years.
Below is the HTML table code comparing the financials and debt year-on-year based on the provided text:
MetricFY 2024FY 2025 (Expected)Change
Revenues (£ million)128.8166-169 (168-171 CC)~30% increase
Operating EBITDA (£ million)(15.3) lossMid-to-high single-digit (CC)Pivot to profitability
Underlying Operating EBITDA (£ million)N/ALow single-digit (CC)N/A
Contracted Value of Client Orders (£ million)18622420% increase
Revenue Backlog (£ million)~150~204~36% increase
Gross Cash Position (£ million)N/A96.9N/A
Net Cash Position (£ million)N/A55.4N/A
Debt (Loan Facility Drawn, $ million)N/A60 (of which $50 million used to repay existing facility)N/A
### Key Notes: 1. **Revenues**: FY 2025 revenues are expected to increase by ~30% compared to FY 2024. 2. **Operating EBITDA**: FY 2025 is expected to pivot to mid-to-high single-digit profitability from a loss in FY 2024. 3. **Contracted Value of Client Orders**: Increased by 20% year-on-year. 4. **Revenue Backlog**: Increased by ~36% year-on-year. 5. **Cash Position**: FY 2025 shows a strengthened balance sheet with gross cash of £96.9 million and net cash of £55.4 million. 6. **Debt**: A new loan facility of $125 million was entered, with $60 million drawn, $50 million of which was used to repay existing debt. This table provides a clear year-on-year comparison of key financials and debt metrics.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 8
OXB 06:01
Oxford BioMedica PLC
Preliminary results for the year ended 31 Dec 2025
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Oxford Biomedica PLC (OXB) reported strong preliminary results for the year ended 31 December 2025, highlighting strategic execution, robust revenue growth, and positive Operating EBITDA. Key financial highlights include
**Revenue Growth** 33% increase to £170.9 million (constant currency), driven by growth in lentiviral vector GMP manufacturing, increased client progression, and expansion in procurement and storage services.
**Operating EBITDA** Achieved a profit of £8.1 million (constant currency), up from a £15.3 million loss in 2024, reflecting revenue growth and cost management.
**Revenue Backlog** Increased by 36% to £204 million, indicating strong future revenue potential.
**Strategic Expansion** Acquired an FDA-approved commercial-scale viral vector manufacturing facility in Durham, NC, enhancing global CDMO capabilities.
**New Commercial Agreement** Signed a multi-year agreement with Bristol Myers Squibb (BMS) for lentiviral vector manufacturing post-period.
**Financial Guidance** Projected 2026 revenues of £220-240 million with a 10% Operating EBITDA margin, and medium-term revenue growth of 25-30% with margins rising to at least 20% by 2027.
Operationally, OXB expanded its global CDMO network, improved efficiency, and strengthened its balance sheet through equity raises and loan facilities. The company also advanced its innovation efforts, particularly in AAV and lentiviral vector technologies, and enhanced its ESG commitments. The acquisition of the Durham facility and strategic partnerships underscore OXBs position as a global leader in cell and gene therapy CDMO services, poised for sustained growth and profitability.
Financial Metric20242025Year-on-Year Change
Revenue£128.8 million£170.9 million (CC)33% increase
Operating EBITDA£(15.3) million£8.1 million (CC)Profitability achieved
Underlying Operating EBITDA (excluding Durham gain)N/A£3.3 million (CC)New metric introduced
Revenue BacklogN/A£204 million36% increase
Contracted Value of Orders£186 million£224 million20% increase
Net Cash£20.6 million£55.4 million169% increase
Debt (Loans)£39.79 million£41.488 million4.3% increase
### Key Observations: 1. **Revenue Growth**: Revenue increased by 33% year-on-year, driven by growth in lentiviral vector GMP manufacturing, increased client progression through clinical development, and growth in procurement and storage services. 2. **EBITDA Improvement**: Operating EBITDA turned positive, achieving £8.1 million (CC) compared to a loss of £15.3 million in 2024, reflecting strong revenue growth and cost control. 3. **Debt Increase**: Debt increased slightly by 4.3%, primarily due to new loans drawn down and interest accruals. 4. **Cash Position**: Net cash position significantly improved, increasing by 169% to £55.4 million, supported by equity raises and improved operating performance. 5. **Order Book Strength**: Revenue backlog and contracted value of orders both increased substantially, indicating strong future revenue visibility and continued growth.
OXB 06:01
Oxford BioMedica PLC
Licensing agreement with VVMF
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
Oxford Biomedica (OXB) has entered into a licensing and option agreement with Viral Vector Manufacturing Facility (VVMF), an Australian CDMO, granting VVMF access to OXBs proprietary AAV and LV viral vector platforms. This five-year agreement, with a low single-digit million license fee and potential future payments, supports VVMFs development of viral vector manufacturing capabilities, particularly in the APAC region. The collaboration extends OXBs global reach, reinforces its position as a trusted viral vector CDMO, and positions Australia as a regional hub for high-quality cell and gene therapy manufacturing.
Agreement
OXB 06:54
Oxford BioMedica PLC
Admission to Trading
OXB 10:46
Oxford BioMedica PLC
Admission to Trading Application
OXB 06:01
Oxford BioMedica PLC
Capital Markets Day and investor conferences
OXB 06:01
Oxford BioMedica PLC
Total Voting Rights
OXB 11:34
Oxford BioMedica PLC
Response to Rule 2.8 Announcement
OXB 06:04
Oxford BioMedica PLC
Full year Trading Update and Notice of Results
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Oxford Biomedica PLC (OXB) released a full-year trading update for 2025, highlighting strong financial performance and strategic progress. Key points include
1. **Revenue Growth**FY 2025 revenues are expected to reach £166-169 million, a 30% increase from 2024 and nearly 90% growth since 2023, driven by sustained demand for viral vector services and operational efficiency.
2. **EBITDA Profitability**OXB achieved EBITDA profitability in 2025, with mid-to-high single-digit £ million Operating EBITDA, including a non-recurring gain from the Durham, NC acquisition. Underlying EBITDA (excluding the acquisition) is in line with guidance at low single-digit £ million.
3. **Contracted Orders**The contracted value of client orders increased by 20% to £224 million, reflecting strong demand from existing and new clients.
4. **Financial Position**OXB strengthened its balance sheet with a £60 million equity raise and a new $125 million loan facility, supporting capacity expansion and growth initiatives.
5. **Future Outlook**The company reiterated its guidance, expecting FY 2026 revenues of £220-240 million, with 25-30% annual growth in 2027 and 2028. EBITDA margins are projected to exceed 10% in 2026 and reach at least 20% in 2027, with long-term potential to approach 30%.
6. **Preliminary Results**OXB will announce its preliminary results for 2025 on March 26, 2026, with a virtual analyst briefing led by CEO Dr. Frank Mathias.
The update underscores OXBs successful execution of its CDMO strategy, strong commercial momentum, and optimism for continued growth and profitability in the coming years.
Below is the HTML table code comparing the financials and debt year-on-year based on the provided text:
MetricFY 2024FY 2025 (Expected)Change
Revenues (£ million)128.8166-169 (168-171 CC)~30% increase
Operating EBITDA (£ million)(15.3) lossMid-to-high single-digit (CC)Pivot to profitability
Underlying Operating EBITDA (£ million)N/ALow single-digit (CC)N/A
Contracted Value of Client Orders (£ million)18622420% increase
Revenue Backlog (£ million)~150~204~36% increase
Gross Cash Position (£ million)N/A96.9N/A
Net Cash Position (£ million)N/A55.4N/A
Debt (Loan Facility Drawn, $ million)N/A60 (of which $50 million used to repay existing facility)N/A
### Key Notes: 1. **Revenues**: FY 2025 revenues are expected to increase by ~30% compared to FY 2024. 2. **Operating EBITDA**: FY 2025 is expected to pivot to mid-to-high single-digit profitability from a loss in FY 2024. 3. **Contracted Value of Client Orders**: Increased by 20% year-on-year. 4. **Revenue Backlog**: Increased by ~36% year-on-year. 5. **Cash Position**: FY 2025 shows a strengthened balance sheet with gross cash of £96.9 million and net cash of £55.4 million. 6. **Debt**: A new loan facility of $125 million was entered, with $60 million drawn, $50 million of which was used to repay existing debt. This table provides a clear year-on-year comparison of key financials and debt metrics.

Today's AI

Today's AI Starts With News

1 live catalyst is opening Today’s AI for OXB.

Start with the live headline tape first. Today’s AI findings sit next, and the AI Blend stack drops lower once the news context is framed. Financial Forecastist now feeds the blend too.
Live Tape Data 2026-03-26 Blend Lower Down
Read the alert tape first, then open Today’s AI findings. Use AI Expand on any card to open the AI explanation, results tables and financial forecast rows instantly.
1 Today
Front Of Desk
Oxford BioMedica PLC has fresh news flow live now, so Today’s AI is leading with the tape before the blended signal stack below.
Single-Ticker Today's AI
OXB signal theatre built from scored market catalysts, automated AI forecasts, financial forecasting and live trigger logic.

This is the ticker-specific Today’s AI desk for Oxford BioMedica PLC. It compresses the live catalyst tape, bullish and bearish scoring, AI price forecasts, financial forecasting and trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI + Financial Blend Buy / Sell Trigger Engine Today's AI Findings
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full OXB Today’s AI cockpit.

Subscription turns this tab into a live signal desk with today’s news findings at the top, AI plus financial blend comparisons at the bottom, buy and sell trigger logic, and the full findings ledger behind every scored row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific Today’s AI stack, sentiment gauges, AI blend stage, and the full findings ledger for OXB on 2026-03-26.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
759.4M
Enterprise Value
327.8M
Public Float
50.3
Broker Target
842.857
Shares Out
120.9M
Long Interest
94
Short Interest
6
Exchange
LSE
Currency Code
GBX
ISIN
GB00BDFBVT43
Market
LSE - MAIN MARKET
Sector
Pharmaceuticals and Biotechnology
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

News And Alerts First

1 live alert now opens the financials desk for OXB.

Start with the headline flow and alert tape first. Then drop straight into Financial Forecastist below for the revenue path, EPS shape, cash pressure and balance-sheet read while the catalyst context is still hot.
Live Alerts Data 2026-03-26 Forecastist Below
Read the alert tape first, then move into Financial Forecastist below. Use AI Expand on any catalyst card to open the AI explanation and results tables without losing the ticker context.
1 Alerts
Front Of Desk
Oxford BioMedica PLC has fresh filing flow live now, so the tape is framing the revenue, leverage and valuation story below.
Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-04-09
Net Debt
9.8M
Cash
96.9M
EPS
-0.27
Net Income
-30.1M
Revenue
168.7M
Enterprise Value
327.8M
Trailing PE
-
Forward PE
208.3333
Price Sales TTM
4.5002
Price Book MRQ
8.3131
EV Revenue
4.8039
EV EBITDA
336.0766
Financial Forecastist

Mixed financial engine

Revenue is accelerating +105.5% against the prior comparable period. Net margin is expanding by 231.7 pts. Net debt is building +26.0%.

Revenue +105.5% Net Income -96.6% FCF -60.6% Current Ratio 2.20x Forward Rev 0
Mixed
Quarter Revenue
95.5M
+105.5%
vs prior comparable quarter
Net Margin
-3.9%
+231.7 pts
profitability pulse
Free Cash Flow
-11.1M
-60.6%
cash conversion
Net Debt / EBITDA
-1.0x
+26.0%
lower is cleaner
Revenue Engine

Latest quarter printed 95.5M with the top line pushing higher against the last comparable period.

Profit Stack

Net income landed at -3.8M and the margin profile is broadening. That usually tells us whether operating leverage is finally kicking in.

Balance-Sheet Pressure

Cash sits near 96.9M while net debt is 9.8M. The leverage stack is moving the wrong way.

Quarterly Revenue Runway

Actual revenue bars, consensus revenue where available, plus the terminal model path.

Profit And Cash Conversion

Net income and free cash flow moving together is usually what separates genuine improvement from noise.

Balance-Sheet Pressure

Cash, net debt and liquidity tell us whether the business is strengthening or just surviving.

Annual Power Curve

Longer-cycle revenue and net income help frame whether the company is compounding or rolling over.
Q3 2023
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q1 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q2 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q3 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
FY 2026
Consensus
228.9M
Revenue Path
-0.10
EPS / Earnings
Growth cue +0.6%
FY 2027
Consensus
289.4M
Revenue Path
0.13
EPS / Earnings
Growth cue +2.3%

Quarterly Statement Tape

Last 6 Quarters
Period Revenue Net Income FCF Net Debt
Q4 2025 95.5M -3.8M -11.1M 9.8M
Q2 2025 73.2M -26.4M 845.0K 51.5M
Q4 2024 78.0M -10.7M -14.5M 48.1M
Q2 2024 50.8M -32.5M -44.0M 28.9M
Q4 2023 46.5M -109.5M -28.1M 7.7M
Q2 2023 43.1M -48.0M -13.1M -16.3M

Annual Financial Power

Last 5 Years
Period Revenue Net Income EBITDA FCF
FY 2025 168.7M -30.1M -33.5M -10.2M
FY 2024 128.8M -43.2M -14.3M -58.1M
FY 2023 89.5M -157.5M -148.6M -38.3M
FY 2022 140.0M -39.2M -10.8M -28.9M
FY 2021 142.8M 19.0M 33.2M 16.0M

Structure DNA

Market Structure DNA

Balanced Structure profile with trend broken

Price is -29.8% through the 52-week range, -90.2% vs 50DMA and -89.6% vs 200DMA. 78.8% of the register is locked by institutions and insiders, leaving 21.2% free float. Capital rhythm reads no cadence with forward yield near 0.0% and payout around 0.0%.

Trend broken Institutional gravity Moderate income rhythm As Of 2026-04-19
Balanced Structure
Structure Score
40.2 / 100
Balanced Structure
Trend Stack
-90.2% / -89.6%
vs 50DMA / 200DMA
52W Position
-29.8%
auction position inside the yearly range
Ownership Lock
78.8%
58.0% institutions | 20.8% insiders
Pressure Pocket
21.2% free float
Vendor short-float fields were not supplied
Capital Rhythm
No cadence
Yield 0.0% | payout 0.0%
Trend Runway

Implied spot is 64.10 with the stock -90.2% vs 50DMA and -89.6% vs 200DMA. The tape is sitting -29.8% through the 52-week range, which frames the regime as trend broken.

Ownership Register

Institutions hold about 58.0% and insiders about 20.8%, locking roughly 78.8% of the register and leaving 21.2% in free float. That reads as institutional gravity.

Pressure Pocket

The API did not return a usable short-float field for this ticker, so the pressure score leans more on float lock and crowding than a full short ledger.

Capital Rhythm

Dividend cadence reads no cadence with - event(s) in the last full year, a five-year average of -, and stability score 0.0/100. Forward yield sits near 0.0% while payout is around 0.0%.

Structure Score

One-glance gauge for the current market-structure regime.

Pillar Radar

Trend, ownership, pressure, and capital rhythm mapped on one wheel.

Position And Float Balance

Shows whether the stock is extended, tightly held, or carrying capital-return support.

Dividend Cadence Tape

Historical dividend-event counts help reveal how dependable the income rhythm has been.

Dividend Cadence Ledger

No cadence
Year Dividend Count Context
Dividend history has not been normalized yet.

Structure Facts

Live Snapshot
Implied Spot
64.10
derived from market cap / shares
52W High
962.00
upper auction edge
52W Low
270.00
lower auction edge
Beta
1.10
volatility character
Shares Out
120.9M
fully diluted count
Shares Float
60.8M
tradable register
Shares Short
0
borrowed stock
Short Ratio
0.0x
days-to-cover style read
Ex-Dividend
-
next ex-date not supplied
Dividend Pay
-
payment date not supplied
Last Split
1:50
2018-05-30

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
34.1457
Institutions As Of
2025-11-03
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
4
Sale Director Dealing
3
Purchase TR1
10
Sale TR1
2
Broker Coverage Rows
8
Institution Holders Tracked
5
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

News And Alerts First

The alert tape opens the door for OXB, and AI Charts sits just below.

Start with the headline flow and live catalyst tape first. Then move straight into AI Charts below for price reaction, AI targets, chart structure and catalyst beacons while the news context is still hot.
Live Tape Data 2026-03-26 AI Charts Below
Read the alert tape first, then move into AI Charts below. Use AI Expand on any catalyst card to open the AI explanation and results tables instantly.
1 Today
Catalyst Pulse
Oxford BioMedica PLC has fresh news flow live now, so the tape is framing the chart workspace below.
AI Charts Studio
OXB Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-03-26 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
Desk Snapshot Member Login
Indicators0
Technicals0
AI Forecast 31.33%
RSI Gauge
Price Change
AI Forecast